NCT07422831Enrolling by invitation
T2D Intermittent Nonprescription Sensors for Informed Glucose Health Tracking
Improving Type 2 Diabetes Management in Primary Care Through Periodic Continuous Glucose Monitoring
Source: ClinicalTrials.gov · Last updated 29 Apr 2026
Brief summary (registry, in English)
The goal of this clinical trial is to learn if periodic use of over-the-counter continuous glucose monitoring (CGM) can support glucose management in people with type 2 diabetes not using insulin being treated in primary care settings. The main questions it aims to answer are: * Is periodic use of CGM every 30 or 90 days for six months associated with reduced A1C compared to usual care at baseline? * Is periodic use of CGM every 30 or 90 days for six months associated with increased time in range and time in tight range compared to usual care at baseline? * Is periodic use of CGM every 90 days over six months associated with non-inferior A1C reduction compared to periodic use of CGM every 30 days? * Are clinician feasibility and acceptability of periodic, OTC CGM higher than for prescription CGM? * How acceptable is periodic, OTC CGM to people with non-insulin-treated type 2 diabetes? Researchers will compare use of periodic CGM every 30 and 90 days to see if less frequent periodic CGM use can support glucose management as effectively as more frequent use. Participants will: * be assigned to one of two groups using the 15-day Dexcom Stelo® glucose biosensor every 30 or 90 days over a six-month period. * receive Stelo devices every 30 or 90 days (as randomized) * complete up to 9 virtual or in-person visits with the study team. * complete 3 fingerstick A1c tests. * wear a blinded CGM device at 3 time points outside of Dexcom Stelo® use. * complete a survey at the end of the study.
- Status (registry)
- Enrolling by invitation
- Study type
- Interventional
- Enrollment
- 188 (estimated)
- First submitted
- 29 Jan 2026
- Start date
- 2 Apr 2026
- Primary completion date
- Dec 2027
- Lead sponsor
- University of Colorado, Denver
- Diseases
- Type 1 diabetes, Type 2 diabetes
- NCT number
- NCT07422831
What you commit to
- Study type: Interventional
- Planned participants: 188
- From 2 Apr 2026 to the primary completion date, Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of insulin in the 12 months prior to screening or planning to initiate insulin during the next 12 months (short-term use of insulin in an inpatient setting is acceptable)
- Concomitant disease or condition that in the opinion of the investigator may compromise patient safety including but not limited to severe mental illness, a diagnosed or suspected eating disorder, or any uncontrolled or chronic medical condition that would interfere with study related tasks or visits
Other illness
- Known presence of a hemoglobinopathy or other condition that is expected to affect the measurement of A1C in the judgment of the investigator
- Known severe allergy to medical grade adhesive, a serious skin condition that could interfere with CGM placement, or extensive tattoos that precludes the use of CGM in an FDA approved location
Lab values
- Use within 30 days of screening visit of any medication that in the opinion of the investigator may exacerbate glucose dysfunction (e.g. systemic corticosteroids)
- End stage renal disease currently managed by dialysis or eGFR \<30 mL/min/1.73m2
Other
- Current or planned use of hydroxyurea (due to interference with CGM)
- Current participation in another interventional study protocol that could impact participation in this study per investigator discretion
- Pregnant or planning to become pregnant within the next 6 months.
- Planning to switch primary care practices in the next 6 months.
Who the study is looking for
- Age ≥ 18 years at time of enrollment
- Diagnosis of type 2 diabetes
- Able to read and understand English (Dexcom Stelo is currently only available in English)
- No real-time or intermittently scanned (Flash) CGM use 12 months prior to enrollment
- Stable medication regimen (medication classes) and dose (equivalent dose if medication has been changed within the same medication class) for any glucose lowering or weight loss medications for 30 days prior to enrollment and willing to not change medications prior to randomization unless safety concerns.
- Cell phone meeting minimum required OS compatibility with Stelo
- Willing to use the study device and download the Stelo app
- Willing and able to complete all study procedures per investigator discretion, including willingness to accept either experimental group (q30 or q90).
- A1C value (from lab data or chart review) greater than or equal to 6.5 in the 6 months prior to enrollment
- Currently receiving primary care in a participating study practice
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Colorado Denver - Anschutz Medical Campus Coordinator of this site? Confirm its status | Aurora | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.